Literature DB >> 36068474

Pharmacogenomics of Opioid Treatment for Pain Management.

Sarahbeth Howes1, Alexandra R Cloutet1, Jaeyeon Kweon2, Taylor L Powell1, Daniel Raza3, Elyse M Cornett4, Alan D Kaye5.   

Abstract

Pain affects approximately 100 million Americans. Pain harms quality of life and costs patients billions of dollars per year. Clinically, nonpharmacologic and pharmacologic therapies can alleviate acute and chronic pain suffering. Opioids are one type of medication used to manage pain. However, opioids can potentially create dependence and substance abuse, and the effects are not consistent in all patients. Pharmacogenomics is the study of the genome to understand the effects of drugs on individual patients based on their genetic information. Through pharmacogenomics, researchers can investigate genetic polymorphisms related to pain that maximize individual patient drug responses and minimize toxicity. This chapter discusses the pharmacogenomics of opioids to treat pain, including individual genetic differences to opioid treatments, opioid pharmacokinetics and pharmacodynamics, and the genetic polymorphisms associated with individual opioid medications.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Acute pain; Chronic pain; Opioids; Pain management; Pharmacogenetics; Pharmacogenomics; Precision medicine

Mesh:

Substances:

Year:  2022        PMID: 36068474     DOI: 10.1007/978-1-0716-2573-6_17

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  44 in total

Review 1.  A possible genetic mechanism underlying individual and interstrain differences in opioid actions: focus on the mu opioid receptor gene.

Authors:  Wenhua Han; Soichiro Ide; Ichiro Sora; Hideko Yamamoto; Kazutaka Ikeda
Journal:  Ann N Y Acad Sci       Date:  2004-10       Impact factor: 5.691

Review 2.  Opioid pharmacology.

Authors:  Andrea M Trescot; Sukdeb Datta; Marion Lee; Hans Hansen
Journal:  Pain Physician       Date:  2008-03       Impact factor: 4.965

Review 3.  Pharmacogenomics in pain treatment.

Authors:  Ana M Peiró; Beatriz Planelles; Gabriella Juhasz; György Bagdy; Frédéric Libert; Alain Eschalier; Jérôme Busserolles; Beata Sperlagh; Adrián Llerena
Journal:  Drug Metab Pers Ther       Date:  2016-09-01

Review 4.  Pharmacogenomics of Pain Management: The Impact of Specific Biological Polymorphisms on Drugs and Metabolism.

Authors:  Elyse M Cornett; Michelle A Carroll Turpin; Allison Pinner; Pankaj Thakur; Tamizh Selvan Gnana Sekaran; Harish Siddaiah; Jasmine Rivas; Anna Yates; G Jason Huang; Anitha Senthil; Narjeet Khurmi; Jenna L Miller; Cain W Stark; Richard D Urman; Alan David Kaye
Journal:  Curr Oncol Rep       Date:  2020-02-06       Impact factor: 5.075

5.  The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease.

Authors:  P Klepstad; T T Rakvåg; S Kaasa; M Holthe; O Dale; P C Borchgrevink; C Baar; T Vikan; H E Krokan; F Skorpen
Journal:  Acta Anaesthesiol Scand       Date:  2004-11       Impact factor: 2.105

Review 6.  Personalizing pediatric pain medicine: using population-specific pharmacogenetics, genomics, and other -omics approaches to predict response.

Authors:  Nathalia Jimenez; Jeffrey L Galinkin
Journal:  Anesth Analg       Date:  2015-07       Impact factor: 5.108

7.  A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia.

Authors:  Alex T Sia; Yvonne Lim; Eileen C P Lim; Rachelle W C Goh; Hai Yang Law; Ruth Landau; Yik-Ying Teo; Ene Choo Tan
Journal:  Anesthesiology       Date:  2008-09       Impact factor: 7.892

8.  The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system.

Authors:  Benjamin B Land; Michael R Bruchas; Julia C Lemos; Mei Xu; Erica J Melief; Charles Chavkin
Journal:  J Neurosci       Date:  2008-01-09       Impact factor: 6.167

9.  Genetic Analysis of Mu and Kappa Opioid Receptor and COMT Enzyme in Cancer Pain Tunisian Patients Under Opioid Treatment.

Authors:  Imen Chatti; Jean-Baptiste Woillard; Amira Mili; Isabelle Creveaux; Ilhem Ben Charfeddine; Jihène Feki; Sarah Langlais; Leila Ben Fatma; Ali Saad; Moez Gribaa; Frédéric Libert
Journal:  Iran J Public Health       Date:  2017-12       Impact factor: 1.429

10.  Optimizing use of opiates in the management of cancer pain.

Authors:  Mario Mandalà; Cecilia Moro; Roberto Labianca; Marco Cremonesi; Sandro Barni
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.